High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: The effect of higher MIC-related pharmacokinetic parameters on efficacy

Journal of Infection

Volumn 58, Issue 3, 2009, Pages 220-226

  Murillo, Oscar ^a   Eugenia Pachon M ^a   Euba, Gorane ^a   Verdaguer, Ricard ^b   Tubau, Fe ^b   Cabellos, Carmen ^a   Cabo, Javier ^b   Gudiol, Francesc ^a   Ariza, Javier ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Animal models; Device infection; Fluoroquinolones; S. aureus

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; FOREIGN BODY; HALF LIFE TIME; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; FOREIGN BODIES; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, ANIMAL; OFLOXACIN; QUINOLINES; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 61349178830     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.01.005     Document Type: Article

References (46)

1. Widmer A.F., Gaechter A., Ochsner P.E., and Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 14 (1992) 1251-1253
2. Drancourt M., Stein A., Argenson J.N., Zannier A., Curvale G., and Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 37 (1993) 1214-1218
3. Drancourt M., Stein A., Argenson J.N., Roiron R., Groulier P., and Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampin. J Antimicrob Chemother 39 (1997) 235-240
4. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 279 (1998) 1537-1541
5. Widmer A.F., Frei R., Rajacic Z., and Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 162 (1990) 96-102
6. Zimmerli W., Frei R., Widmer A.F., and Rajacic Z. Microbiological test to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 33 (1994) 959-967
7. Blaser J., Vergeres P., Widmer A.F., and Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 39 (1995) 1134-1139
8. Costerton J.W., Stewart P., and Greenberg E.P. Bacterial biofilm: a common cause of persistent infections. Science 284 (1999) 1318-1322
9. Stewart P.S., and Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 358 (2001) 135-138
10. Zimmerli W., Trampuz A., and Ochsner P.E. Prosthetic-joint infections. N Engl J Med 351 (2004) 1645-1654
11. Lucet J.C., Herrmann M., Rohner P., Auckenthaler R., Waldvogel F.A., and Lew D.P. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 34 (1990) 2312-2317
12. Chuard C., Herrmann M., Vaudaux P., Waldvogel F.A., and Lew D.P. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 35 (1991) 2611-2616
13. Vaudaux P., Francois P., Bisognano C., Schrenzel J., and Lew D.P. Comparison of levofloxacin, alatrofloxacin and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 1503-1509
14. Murillo O., Domenech A., Euba G., Verdaguer R., Tubau F., Cabo J., et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infection 57 (2008) 229-235 10.1016/jinf.2008.07.003
15. Chuard C., Lucet J.C., Rohner P., Herrmann M., Auckenthaler R., Waldvogel F.A., et al. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 163 (1991) 1369-1373
16. Murillo O., Domenech A., Garcia A., Tubau F., Cabellos C., Gudiol F., et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylocococcus aureus. Antimicrob Agents Chemother 50 (2006) 4011-4017
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved Standard M7-A6 (2005), CLSI, Wayne, PA, USA
18. Zhao X., and Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 (2001) S147-S156
19. Drlica K., and Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 44 (2007) 681-688
20. National Comittee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents M26-A (1999), NCCLS, Villanova, PA, USA
21. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
22. Ryan M., Hodges B., Spencer G.R., and Harding S.M. Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob Agents Chemother 22 (1982) 995-998
23. Trampuz A., Wenk M., Rajacic Z., and Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 44 (2000) 1352-1355
24. Chow A.T., Fowler C., Williams R., Morgan N., Kaminski S., and Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 45 (2001) 2122-2125
25. Conte Jr. J.E., Golden J.A., McIver M., and Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 28 (2006) 114-121
26. Sullivan J.T., Woodruff M., Lettieri J., Agarwal V., Krol G.J., Lesse P.T., et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 43 (1999) 2793-2797
27. Krasemann C., Meyer J., and Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 32 (2001) S51-S63
28. Stass H., Dalhoff A., Kubitza D., and Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42 (1998) 2060-2065
29. Chapin-Robertson K., and Edberg S.C. Measurements of antibiotics in human body fluids: techniques and significance. In: Lorian V. (Ed). Antibiotics in laboratory medicine (1991), Williams and Wilkins, New York 295-366
30. Craig W. Does the dose matter?. Clin Infect Dis 33 (2001) S233-S237
31. Van Bambeke F., Michot J.M., Van Eldere J., and Tulkens P.M. Quinolones in 2005: an update. Clin Microbiol Infect 11 (2005) 256-280
32. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40 (1997) 639-651
33. Lister P.D. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 32 (2001) S33-S38
34. Firsov A., Lubenko I., Vostrov S., Portnoy Y., and Zinner S. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother 49 (2005) 2642-2647
35. Forrest A., Nix D., Ballow C., Goss T., Birmingham M., and Schentag J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
36. Andes D., and Craig W. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19 (2002) 261-268
37. Piddock L. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 38 (1994) 163-169
38. Lewin C.S., Morrissey I., and Smith J.T. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis 10 (1991) 240-248
39. Crumplin G.C., and Smith J.T. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 8 (1975) 251-261
40. Hyatt J.M., Nix D., and Schentag J. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother 38 (1994) 2730-2737
41. Firsov A., Zinner S., Vostrov S., Portnoy Y., and Lubenko I. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 50 (2002) 533-539
42. Barcia-Macay M., Seral C., Mingeot-Leclercq M.P., Tulkens P., and Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50 (2006) 841-851
43. Nguyen H.A., Grellet J., Dubois V., Saux M.C., and Quentin C. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus. J Antimicrob Chemother 59 (2007) 755-758
44. Thomas J., Forrest A., Bhavnani S., Hyatt J., Cheng A., Ballow C., et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42 (1998) 521-527
45. Firsov A., Vostrov S., Lubenko I., Drlica K., Portnoy Y., and Zinner S. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1604-1613
46. Cui J., Liu Y., Wang R., Tong W., Drlica K., and Zhao X. The mutant selection window in rabbits infected with Staphylocococcus aureus. J Infect Dis 194 (2006) 1601-1608